

# CONTENTS

<b>Executive Summary</b> .....	i
<b>Assessment of the <i>Special Statutory Funding Program For Type 1 Diabetes Research</i></b> .....	1
<b>Goal I: Identify the Genetic and Environmental Causes of Type 1 Diabetes</b> .....	26
Highlights of Scientific Progress .....	28
Evaluation of Major Research Consortia, Networks, and Resources Related to the Identification of Genetic and Environmental Causes of Type 1 Diabetes .....	30
Type 1 Diabetes Genetics Consortium (T1DGC) .....	30
The Environmental Determinants of Diabetes in the Young (TEDDY) .....	34
Search for Diabetes in Youth (SEARCH) .....	39
Type 1 Diabetes Mouse Repository (T1DR) .....	45
Type 1 and Type 2 Diabetes: Common Links .....	47
Patient Profile: Berg Family .....	49
The PancChip: A Powerful Tool for Diabetes Research .....	52
Emerging Research Opportunities Resulting from the <i>Special Statutory Funding Program for Type 1 Diabetes Research</i> .....	56
<b>Goal II: Prevent or Reverse Type 1 Diabetes</b> .....	58
Highlights of Scientific Progress .....	60
Evaluation of Major Research Consortia, Networks, and Resources Related to Preventing and Reversing Type 1 Diabetes .....	62
Type 1 Diabetes TrialNet (TrialNet) .....	62
Immune Tolerance Network (ITN) .....	69
Cooperative Study Group for Autoimmune Disease Prevention (Prevention Centers) .....	74
Standardization Programs: Diabetes Autoantibody Standardization Program (DASP); C-peptide Standardization; and Improving the Clinical Measurement of Hemoglobin A1c (HbA1c) .....	78
Trial To Reduce IDDM in the Genetically at-Risk (TRIGR) .....	83
Evaluation of Investigator-Initiated Research .....	87
Immune Tolerance .....	88
Investigator Profile: Kevan Herold, MD .....	89
Patient Profile: Katie and Ellie Clark .....	92
Emerging Research Opportunities Resulting from the <i>Special Statutory Funding Program for Type 1 Diabetes Research</i> .....	94
<b>Goal III: Develop Cell Replacement Therapy</b> .....	96
Highlights of Scientific Progress .....	98
Evaluation of Major Research Consortia, Networks, and Resources Related to the Development of Cell Replacement Therapies .....	101
Beta Cell Biology Consortium (BCBC) .....	101
Non-Human Primate Transplantation Tolerance Cooperative Study Group (NHPCSG) .....	105

Immunobiology of Xenotransplantation Cooperative Research Program .....	109
Clinical Islet Transplantation (CIT) Consortium.....	111
Islet Cell Resource Centers (ICRs).....	115
Collaborative Islet Transplant Registry (CITR) .....	120
Evaluation of Investigator-Initiated Research .....	123
Advancing Islet Transplantation.....	125
Patient Profile: Karla Edge.....	128
Emerging Research Opportunities Resulting from the <i>Special Statutory Funding Program for Type 1</i> <i>Diabetes Research</i> .....	132
<b>Goal IV: Prevent or Reduce Hypoglycemia in Type 1 Diabetes</b> .....	134
Highlights of Scientific Progress.....	136
Evaluation of the Major Research Trial Network Testing Technology To Prevent or Reduce Hypoglycemia in Type 1 Diabetes .....	139
Diabetes Research in Children Network (DirecNet) .....	139
Evaluation of Investigator-Initiated Research .....	143
Developing Better Ways To Treat Diabetes: A Closed Loop Artificial Pancreas.....	144
Patient Profile: Casey Burkhalter .....	146
Patient Profile: The Beauregard Family.....	149
Emerging Research Opportunities Resulting from the <i>Special Statutory Funding Program for Type 1</i> <i>Diabetes Research</i> .....	153
<b>Goal V: Prevent or Reduce the Complications of Type 1 Diabetes</b> .....	154
Highlights of Scientific Progress.....	156
Evaluation of Major Research Consortia, Networks, and Resources Related to Preventing or Reversing the Complications of Type 1 Diabetes .....	159
Epidemiology of Diabetes Interventions and Complications (EDIC) .....	159
Genetics of Diabetic Complications .....	164
Diabetic Retinopathy Clinical Research Network (DRCR.net) .....	170
Animal Models of Diabetic Complications Consortium (AMDCC) .....	174
Evaluation of Investigator-Initiated Research .....	178
Story of Discovery: The DCCT/EDIC Research Group.....	180
Angiogenesis: A New Frontier in Diabetes Research .....	182
Patient Profile: Dana Lewis .....	185
Emerging Research Opportunities Resulting from the <i>Special Statutory Funding Program for Type 1</i> <i>Diabetes Research</i> .....	187
<b>Goal VI: Attract New Talent and Apply New Technologies to Research on Type 1 Diabetes</b> .....	190
Highlights of Scientific Progress.....	192

Evaluation of Major Efforts To Bridge Disciplines, Attract New Talent, and Apply New Technologies to Research on Type 1 Diabetes .....	194
Bench to Bedside Research on Type 1 Diabetes and Its Complications .....	194
Innovative Partnerships in Type 1 Diabetes Research .....	197
Research Training and Career Development in Pediatric Diabetes .....	200
Type 1 Diabetes—Rapid Access to Intervention Development (T1D—RAID) .....	203
Evaluation of Investigator-Initiated Research .....	206
Investigator Profile: Andrew Norris, MD, PhD .....	208
Innovative Partnerships in Type 1 Diabetes Research: A Novel Co-Principal Investigator Mechanism .....	210
Emerging Research Opportunities Resulting from the <i>Special Statutory Funding Program for Type 1 Diabetes Research</i> .....	211
<b>Appendix 1: Allocation of the <i>Special Statutory Funds for Type 1 Diabetes Research</i></b> .....	212
<b>Appendix 2: Type 1 Diabetes Consortia Coordination</b> .....	250
<b>Appendix 3: Supplemental Material on the Planning and Implementation of the <i>Special Funding Program</i></b> .....	266
<b>Appendix 4: Supplemental Material on Scientific Conferences, Workshops, and Meetings Relevant to Type 1 Diabetes and Its Complications</b> .....	282
<b>Appendix 5: Supplemental Material on the Evaluation of the <i>Special Funding Program</i></b> .....	294
<b>Appendix 6: Advances and Emerging Opportunities in Type 1 Diabetes Research: A Strategic Plan</b> .....	306
<b>Appendix 7: Acronyms and Abbreviations</b> .....	314
<b>Acknowledgments</b> .....	320